The discovery of a new sructural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines

Molecular Cancer Therapeutics

Volumn 3, Issue 1, 2004, Pages 1-9

  Hamdouchi, Chafiq ^a   Keyser, Heather ^a   Collins, Elizabeth ^a   Jaramillo, Carlos ^b   De Diego, Jose Eugenio ^b   Spencer, Charles D ^a   Dempsey, Jack Alan ^a   Anderson, Bryan D ^a   Leggett, Tillie ^a   Stamm, Nancy B ^a   Schultz, Richard M ^a   Watkins, Scott A ^a   Cocke, Kim ^a   Lemke, Stephanie ^a   Burke, Teresa F ^a   Beckmann, Richard P ^a   Dixon, Jeffrey T ^a   Gurganus, Thomas M ^a   Rankl, Nancy B ^a   Houck, Keith A ^a   Zhang, Faming ^a   Vieth, Michal ^a   Espinosa, Juan ^b   Timm, David E ^a   Campbell, Robert M ^a   Patel, Bharvin K R ^a   Brooks, Harold B ^a   more..

^a ELI LILLY AND COMPANY   (United States)

^b ELI LILLY AND COMPANY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINOIMIDAZO[1,2 A]PYRIDINE DERIVATIVE; CASPASE 3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; CASP3 PROTEIN, HUMAN; CASPASE; CDK2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 2; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; WESTERN BLOTTING; X RAY CRYSTALLOGRAPHY; CELL CYCLE; CELL DIVISION; CELL STRAIN HCT116; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; IC 50; METABOLISM; PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASES; CDC2-CDC28 KINASES; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; DRUG DESIGN; ENZYME INHIBITORS; HCT116 CELLS; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; PHOSPHORYLATION; PYRIDINES; RETINOBLASTOMA PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4444240719     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-7.
2. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995;11:211-9.
3. Hunter T. Oncoprotein networks. Cell. 1997;88:333-46.
4. Malumbres M, Barbacid M. Milestones in cell division: to cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1:222-31.
5. Stein G, Baserga R, Giordano A, Denhardt DT. The molecular basis of cell cycle control. New York: John Wiley & Sons; 1998. p. 389.
6. Pines J. Cyclins and cyclin-dependent kinases: take your partners. Trends Biochem Sci. 1993;18:195-7.
7. Gillet CE, Barnes DM. Demystified cell cycle. J Clin Pathol. 1998;51:310-6.
8. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of CDKs, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol. 1999;287:821-8.
9. Volm M, Komagi R. Relevance of proliferative and pro apoptotic factors in non small cell lung cancer for patient survival. Br J Cancer. 2000;82:1747-54.
10. Dong YL, Sui L, Tai Y, Sukimoto K, Tokuda M. The overexpression of cyclin dependent kinase (CDK) 2 in laryngeal squamous cell carcinomas. Anticancer Res. 2001;21:103-8.
11. Li JH, Miki H, Ohmori M, Wu F, Funamoto Y. Expression of cyclin E and cyclin dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma. Hum Pathol. 2001;32:945-53.
12. Mihara MS, Shintani S, Nakahara Y, Kiyota A, Ueyama Y, Matsumura T, et al. Overexpression of CDK2 is a prognostic indicator of oral cancer progression. J Jpn Cancer Res. 2001;92:352-60.
13. Muller-Tidow C, Metzger R, Kugler K, Diederichs S, Idos G, Thomas M, et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res. 2001;61:647-53.
14. Xu M, Sheppard KA, Peng CY, Yee AS, Piwnica-Worms H. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol Cell Biol. 1994;14:8420-31.
15. Kitagawa M, Higashi H, Jung HK, Suzuki-Takahashi I, Ikeda M, Tamai K, et al. The consensus motif for phosphorylation by cyclin D1-CDK4 is different from that for phosphorylation by cyclin A/E-CDK2. EMBO J. 1996;15:7060-9.
16. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after γ-irradiation. Proc Natl Acad Sci USA. 1999;96:1002-7.
17. Goda T, Funakoshi M, Suhara H, Nishimoto T, Kobayashi H. The N-terminal helix of Xenopus cyclins A and B contributes to binding specificity of the cyclin-CDK complex. J Biol Chem. 2001;276: 15415-22.
18. Sorensen CS, Lukas C, Kramer ER, Peters JM, Bartek J, Lukas J. A conserved cyclin-binding domain determines functional interplay between anaphase-promoting complex-Cdh1 and cyclin A-CDK2 during cell cycle progression. Mol Cell Biol. 2001;21:3692-703.
19. Takeda DY, Wohlschlegel JA, Dutta A. A bipartite substrate recognition motif for cyclin-dependent kinases. J Biol Chem. 2001;276: 1993-7.
20. Haas K, Johannes C, Geisen C, Schmidt T, Karsunky H, Blass-Kampmann S, et al. Malignant transformation by cyclin E and HaRas correlates with lower sensitivity towards induction of cell death but requires functional Myc and CDK4. Oncogene. 1997;15: 2615-23.
21. Karsunky H, Geisen C, Schmidt T, Haas K, Zevnik B, Gau E, et al. Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: evidence for cooperation between cyclin E and Ras but not Myc. Oncogene. 1999;18:7816-24.
22. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA. 1999;96:4325-9.
23. Wadler S. Perspectives for cancer therapies with CDK2 inhibitors. Drug Resist Updat. 2001;4:347-67.
24. Garrett MD, Fattaey A. CDK inhibition and cancer therapy. Curr Opin Genet Dev (England). 1999;9:104-11.
25. Webster KR. The therapeutic potential of targeting the cell cycle. Exp Opin Invest Drugs. 1998;7:865-87.
26. Lees JA, Weinberg RA. Tossing monkey wrenches into the clock: new ways of treating cancer. Proc Natl Acad Sci USA. 1999;96: 4221-3.
27. Gadbois D, Hamaguchi JR, Swank RA, Bradbury EM. Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. Biochem Biophys Res Commun. 1992;184:80-5.
28. Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, et al. Inhibition of cyclin-dependent kinases, Gsk-3β and Ck1 by Hymenialdisine, a marine sponge constituent. Chem Biol. 2000;7: 51-63.
29. Senderowicz AM. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. Hematol-Oncol Clin North Am. 2002;16:1229-53.
30. Hoessel R, Leclerc S, Endicott J, Nobel M, Lawrie A, Tunnah P, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999;1:60-7.
31. Zaharevitz D, Gussio R, Leost M, Senderowicz A, Lahusen T, Kunick C, et al. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 1999;59:2566-9.
32. Vesely J, Havlicek L, Strnad M, Blow J, Donella-Deana A, Pinna L, et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem. 1994;224:771 -86.
33. Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, et al. Phase I clinical and pharmacokinetic study of Flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol. 2002;20:4074-82.
34. Sanderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst. 2000;92: 376-87.
35. Hamdouchi C, Sanchez C, Ezquerra J. Chemoselective arylsulfenylation of 2-amino-imidazo[1,2-a]pyridines by phenyliodine(III) bis(trifluoroacetate) (PIFA). Synthesis. 1998;867-72.
36. De Bondt HL, Rosenblatt J, Janarcik J, Jones HD, Morgan DO, Kim SH. Crystal structure of cyclin-dependent kinase 2. Nature. 1993;363: 595-602.
37. Minor W, Tomchick DR, Otwinowski Z. Strategies for macromolecular synchrotron crystallography. Structure. 2000;8:R105-10.
38. Accelrys I. QUANTA98, 4.6 edition. San Diego, CA: Accelrys, Inc.; 1998.
39. Copeland RA. Enzymes: a practical introduction to structure, mechanism, and data analysis. New York: Wiley-VCH; 1996. p. 306.
40. Lawrie AM, Noble ME, Tunnah P, Brown NR, Johnson LN, Endicott JA. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat Struct Biol. 1997;4:796-801.
41. Vieth M, Cummin DJ. DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors. J Med Chem. 2000;43:3020-32.
42. Vieth M. Molecular recognition in kinases through computational chemistry. Cell Mol Mol Lett. 2001;6:551.
43. Vieth M, Hirst JD, Dominy BN, Daigler H, Brooks CL III. Assessing search strategies for flexible docking. J Comp Chem. 1998;19:1623-31.
44. Vieth M, Hirst JD, Kolinski A, Brooks CL III. Assessing energy functions for flexible docking. J Comp Chem. 1998;19:1612-22.
45. Carrasco RA, Stamm NB, Patel BKR. One-step cellular caspase-3/7 assay. Biotechniques. 2003;34(5):1064-7.
46. Hamdouchi C, de Bias J, del Prado, M, Gruber J, Heinz BA, Vance L. 3-Substituted 2-amino-6-[(E)-1-phenyl-2-N-methylcarbamoylvinyl]-imidazo[1,2-a] pyridines as a novel class of inhibitors of human Rhinovirus: stereospecific synthesis and antiviral activity. J Med Chem. 1999;42: 50-9.
47. Hamdouchi C, de Blas J, Ezquerra J. A novel application of Ullmann coupling reaction for the alkylsulfenylation of 2-amino-imidazo[1,2-a] pyridine. Tetrahedron. 1999;55:541.
48. Hamdouchi C, Ezquerra J, Vega JA, Vaquero JJ, Alvarez-Builla J, Heinz BA. Short synthesis and anti-Rhinoviral activity of imidazo[1,2-a] pyridines: the effect of acyl groups at 3-position. Bioorg Med Chem Lett. 1999;9:1391-4.
49. Noble MEM, Endicott JA. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Pharmacol Ther. 1999;82:269-78.
50. Davies TG, Tunnah P, Meijer L, Marko D, Eisenbrand G, Endicott JA, et al. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure. 2001;9: 389-97.
51. Davies TG, Endicott JA, Noble MEM, Johnson LN, Arris CE, Bentley J, et al. Structural and thermodynamic validation of inactive CDK2 as a template for structure based drug design. Cell Biol Mol Lett. 2001;6:514-5.
52. Burley SK, Petsko GA. Aromatic-aromatic interaction: a mechanism of protein structure stabilization. Science. 1985;229:23-8.
53. Burley SK, Petsko GA. Dimerization energetics of benzene and aromatic amino acid side chains. J Am Chem Soc. 1986;108:7995-8001.
54. Mossmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
55. Pan W, Cox S, Hoess RH, Grafstrom RH. A cyclin D1/cyclin-dependent kinase 4 binding site within the C domain of the retinoblastoma protein. Cancer Res. 2001;61:2885-91.
56. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 2003;3:233-45.
57. Ormerod MG. Flow cytometry. Oxford: IRL Press; 1994. p. 125.